NEW YORK, NY – The National Hemophilia Foundation (NHF), the leading advocacy and education organization for members of the inheritable blood and bleeding disorders community, is pleased to announce Michael Recht, MD, PhD, MBA, has been appointed Chief Medical and Scientific Officer (CMSO). Dr. Recht will join NHF’s executive leadership team in late March and lead the organization's research strategy and priorities, provide scientific guidance on strategic and operating decisions, and serve as a member of the organization's Medical and Scientific Advisory Council (MASAC).

An internationally respected leader in pediatric hematology, Dr. Recht is a Professor of Clinical Pediatrics and member of the Hemophilia Treatment Center and Section of Pediatric Hematology-Oncology at Yale University School of Medicine where he cares for children, adolescents, and young adults affected by bleeding and clotting disorders.

Dr. Recht most recently served as the Chief Science Officer for the American Thrombosis and Hemostasis Network (ATHN where he worked at the strategic and policy level to inform the scientific direction of the organization. He was also director of the Hemophilia Center at Oregon Health & Science University (OHSU) from 2007 until 2020 and director of the Mountain States Hemophilia Network, a collaboration of hemophilia treatment centers in the western United States. He has also participated in over 110 clinical research trials testing new treatments for children with bleeding and clotting disorders, including being a leader in research involving gene therapy for hemophilia.

“After an extensive and competitive search, Dr. Recht’s leadership and experience were the perfect fit for this role,” said Dr. Len Valentino, NHF President & CEO. “His work has improved the lives of people affected by inheritable blood and bleeding disorders, and we are thrilled that this impactful work can continue at NHF.”

“I am excited to help NHF bring the experiences of people who live with bleeding disorders to the forefront of transformational research and examine where research can have the most community impact,” said Dr. Recht. “I am grateful to be able to continue to work in this community that I so deeply treasure and to be able to help prioritize research opportunities for real patient impact.”                                                        



For 75 years, The National Hemophilia Foundation (NHF) has championed research, education, and advocacy for inheritable blood disorders. NHF is dedicated to finding better treatments, preventative measures, and cures for inheritable blood disorders. Founded by patients in 1948, NHF’s impactful programs and initiatives are made possible through the support of a nationwide network of chapters, as well as individuals, partners, and a cooperative agreement with the Centers for Disease Control and Prevention (CDC). Learn more at